Matthew S. Davids, MD of Dana Farber Cancer Institute @DanaFarber discusses a multicenter phase II study of venetoclax plus dose-adjusted R-EPOCH for Richter"™s syndrome.
Read here: https://meetinglibrary.asco.org/record/186876/abstract
Advertisement